CA2391454A1 - Cannabinoid extraction method - Google Patents
Cannabinoid extraction method Download PDFInfo
- Publication number
- CA2391454A1 CA2391454A1 CA 2391454 CA2391454A CA2391454A1 CA 2391454 A1 CA2391454 A1 CA 2391454A1 CA 2391454 CA2391454 CA 2391454 CA 2391454 A CA2391454 A CA 2391454A CA 2391454 A1 CA2391454 A1 CA 2391454A1
- Authority
- CA
- Canada
- Prior art keywords
- extract
- chaff
- cannflavin
- thc
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 36
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 36
- 238000000605 extraction Methods 0.000 title claims description 12
- 239000000284 extract Substances 0.000 claims abstract description 42
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 34
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 34
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 31
- 235000009120 camo Nutrition 0.000 claims abstract description 24
- 235000005607 chanvre indien Nutrition 0.000 claims abstract description 24
- 239000011487 hemp Substances 0.000 claims abstract description 24
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 13
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 22
- 229930186501 cannflavin Natural products 0.000 claims description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- 239000000341 volatile oil Substances 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 9
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 9
- 229950011318 cannabidiol Drugs 0.000 claims description 9
- LXIXAVCVBZBXIY-UHFFFAOYSA-N 2-(5-methyl-2-propan-2-ylcyclohexyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)C)CCC(C)C1 LXIXAVCVBZBXIY-UHFFFAOYSA-N 0.000 claims description 8
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 8
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 8
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 5
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims description 4
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 claims description 4
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- FLTJDUOFAQWHDF-UHFFFAOYSA-N trimethyl pentane Natural products CCCCC(C)(C)C FLTJDUOFAQWHDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 241000218236 Cannabis Species 0.000 claims 3
- IXCUTZUASDSIJO-UHFFFAOYSA-N 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-(3-methylbut-2-enyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=C(CC=C(C)C)C(O)=C3C(=O)C=2)=C1 IXCUTZUASDSIJO-UHFFFAOYSA-N 0.000 claims 2
- HCAWPGARWVBULJ-UHFFFAOYSA-N 6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1C(C)=CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 HCAWPGARWVBULJ-UHFFFAOYSA-N 0.000 claims 1
- MWGFICMOCSIQMV-PXNMLYILSA-N Cannflavin A Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)c(C/C=C(\CC/C=C(\C)/C)/C)c(O)c3)C(=O)C=2)c1 MWGFICMOCSIQMV-PXNMLYILSA-N 0.000 claims 1
- MWGFICMOCSIQMV-LZYBPNLTSA-N Cannflavin A Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C3C(=O)C=2)=C1 MWGFICMOCSIQMV-LZYBPNLTSA-N 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 abstract description 17
- 229960004242 dronabinol Drugs 0.000 description 15
- 240000004308 marijuana Species 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- -1 for example ethanol Chemical compound 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 101100445631 Staphylococcus aureus (strain NCTC 8325 / PS 47) essE gene Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 229940029995 appetite stimulants Drugs 0.000 description 1
- 238000000222 aromatherapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960003453 cannabinol Drugs 0.000 description 1
- 229930191614 cannabinolic acid Natural products 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method of extracting cannabinoids from hemp and/or of producing a whole hemp extract lacking .DELTA.9-THC is herein described. The industrial hemp is harvested and the chaff is thrashed from the seeds. The chaff is then ground and the ground chaff is extracted with an organic solvent. The extract is then loaded onto a chromatographic column selected to fractionate specific cannabinoids. In one embodiment, .DELTA.9-THC is fractionated out of the extract, producing a whole hemp extract lacking .DELTA.9-THC . In other embodiments, specific cannabinoids of interest are fractionated out, thereby producing purified cannabinoids.
Description
CANNABlNOID ~~CTRACT14N METHOD
FIELD OF THE INVENTION
The following invention relates generally to the field of methods of chemical purification: More specifically, the present invention relates to a method of producing natural health products from industrial hemp:
BACKGROUND OF THE tNVENTI:ON
Recently, public interest in Cannahis as medicine has been growing, based in no small part on the fact that Cannabis has long been considered to have medicinal properties, ranging from treatment of cramps, migraines, convulsions;
appetite stimulation and attenuation of nausea and vomiting. In fact; a report issued by the National Academy of Sciences' Institute of Medicine indicated that the active components of marijuana appear to be useful in treating pain, nausea, AIDS-related weight loss or "wasting", muscle spasms in multiple selerosiS as well as other problems. Advocates of medical marijuana argue that it is also useful for glaucoma, Parkinson's disease; Huntington's disease, migraines epilepsy and Alzheimer's dl ease.
Marijuana refers to varieties of Cannabis f~aving a high content of ~9 tetrahydrocannabinol (~9-THC), which is the psychoacfiive ingredient of marijuana whereas industrial hemp refers to varieties ofi the Cannabis plant that have a low content of O9-THC.
The controversy regarding the medicinal use of marijuana is centered not only on what is delivered but on how it is delivered. Specifically, the primary method used-to deliver marijuana into a patient's system is by smoking the marijuana;
however, smoking increases an individual's risk for cancer; Lung damage and emphysema. Furthermore, as discussed above, marijuana does contain high levels of a psychoactive drug, D9-THC. As such; there has been considerable debate as to whether or not the potential health benefits of smoking marijuana outweigh the health benefits.
However, it is of note that d9-THC is only one of a family of about 60 bl and tri- cyclic compounds named cannabinoids: These natural products usually contain a 1;1'-di-methyl-pyrane ring; a variedly derivatized aromatic ring and a variedly unsaturated cyclohexyl ring, and include for example the non-psychoactive cannabinol; cannabidiol and cannabinolic acid: These latter compounds have been suggested to contribute to some of he beneficial effects of Cannabis, such as cell protection, ,immunosuppression and ant-inflammatory properties. This suggests that these non-psychoactive cannabinoids recognize; the same cellular receptors as THC but, due to structural differences, do not have the same side effects.
Clearly, a process is needed for preparing natural health products containing 'the non-restricted compounds present in marijuana to be used for medicinal purposes.
SUMMARY OF THE INDENTION
According to a first aspect of the invention, there is provided a method of preparing a Cannabis extract comprising:
harvesting Cannabis. composed of seed and chaff;
separating the chaff from the seed;
extracting the chaff with a solvent, thereby producing an extract;
passing the extract over a chromatographic column arranged to fractionate 09-THC out of the extract; and collecting the fractions ' lacking D9-THC from the column, thereby producing a whole hemp extract without the d9-THC.
The chaff may be dried and/or the chaff may be ground prior to extraction.
The collected fractions may be concentrated.
The Cannabis may be industrial hemp:
The solvent may be an organic solvent; selected from the group consisting of: a petroleum derived hydrocarbon; toluene; trimethylpentane, a low molecular weight alcohol; ethanol; a low molecular weight chlorinated hydrocarbon;
and dichloromethane.
According to a second aspect of the invention, there is provided a hemp extract isolated according to the abova-describedmethod.
According to a thud aspect of the invention, there is provided a pharmaceutical composition comprising the hemp extract according to the above described method.
According to a fourth aspect of the invention; here is provided a method of extracting a cannabinoid, cannflavin or essential oil from Cannabis comprising:
harvesting Cannabis composed of seed and chaff;
separating the chaff from the sued;
extracting the chaff with a solvent, thereby producing an extract;
passing the extract over a chromatographic column arranged to fractionate the cannabinoid, cartnflavin or essential oil of interest out of the extract;
and collecting the fractions containing the cannabinoid; cannflavin or essential oil of interest from the column, pr~ducing a purified cannabinoid;
cannflavin or essential oil.
The cannabinoid may be selected from the group -consisting of:
cannabidiol (CBD); cannabinof (CBN); cannabigerol (CBG)cannabichromene (CBC);
cannabidivarol (CBDV); tetrahydrocannabidiol (THCBD); tetrahydrocannabigerol (THCBG); tetrahydrocannabichromene (THCBC); tetrahydrocannabidivarol (THCBDV); O$-THC; the carboxylic acid precursors of h~ foregoing compounds;
and related naturally occurring compounds and their derivatives.
The chaff may be dried andlor the chaff may be ground prior to extraction.
The collected fractions: may be concentrated::
The Cannabis may be industriai hemp.
The solvent may be an organic solvent, selected from the group consisting of: a petroleum derived hydrocarbon; toluene; trimethylpentane, a low molecular weight alcohol; ethanol; a low molecular weight chlorinated hydrocarbon;
and dichloromethane.
According to a fifth aspect of the invention, there is provided a purified cannabinoid, cannflavin or essential oil prepared according to the above-described method.
According to a sixth aspect of the invention, there is provided a pharmaceutical composition comprising the purified cannabinoid, cannflavin or 5 essential oil prepared according the above-described method.
The invention will now be described by way of examples, although the invention is not in any way limited to the examples described herein.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.
DEFINITIONS
As used herein, "industrial hemp" refers to varieties of the Cannabis plant that have a low content of ~9-tetrahydrocannabinol (D9-THC).
As used herein, "supercritical fluid" refers to materials that are under sufficient pressure and heat that they are no longer distinctly liquid or gaseous.
As used herein, "cannabinoids" refers to a family of natural products that usually contain a 1,1'-di-methyl-pyrane ring, a variedly derivatized aromatic ring and a variedly unsaturated cyclohexyl ring and their immediate chemical precursors.
Described herein is a method of processing industrial hemp and extracting cannabinoids, cannflavins or essential oils therefrom. In one embodiment, the extract is run over a column that fractionates O9-tetrahydrocannabinol out of the extract, thereby producing an eluent that is free of a9-THC. The eluent may then be concentrated or otherwise treated by means known in the art to produce a natural health product, that is, a whole hemp extract with they ~9-THC removed. In some embodiments, the fractions containing D9-THC may be collected or pooled or the extracted ~9-THC may be eluted. In another embodiment, the extract is run over a column arranged to fractionate a specific cannabinoid or class of cannabinoids other than o9-THC. In this embodiment, the fractions containing the cannabinoid, cannflavin or essential oil or class of cannflavins, cannabinoids or essential oils of interest are collected, thereby producing purified cannabinoid(s), cannflavin(s) and/or essential oil(s). Compounds isolated by this method may include but are by no means limited to, for example, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarol (CBDV), tetrahydrocannabidiol (THCBD), tetrahydrocannabigerol (THCBG), tetrahydrocannabichromene (THCBC), tetrahydrocannabidivarol (THCBDV), O8-THC, the carboxylic acid precursors of the foregoing compounds, and related naturally occurring compounds and their derivatives.
The invention will now be described by way of examples; however, the invention is in no way limited to these examples.
In the example described herein, industrial hemp is harvested and the hemp seeds are threshed from the chaff. The chaff is collected and may then be dried or extracted green. In the embodiment described herein, the chaff is dried and is then finely divided, ground or pulverized. The ground chaff is then extracted with a solvent.
In this embodiment, the time of residency of the ground chaff in the solvent is up to approximately 2-4 hours. Furthermore, the mixing ratio o~f chaff to solvent is such that the chaff can be suspended in the extracting medium during the extraction process.
Specifically, in this embodiment the volume ratio is between 10:1 to 100:1.
The solvent may be an organic solvent, for example, a petroleum derived hydrocarbon such as for example toluene or trimethylpentane, a low molecular weight alcohol such as for example ethanol, or a low molecular weight chlorinated hydrocarbon such as for example dichloromethane. As will be appreciated by one knowledgeable in the art, other suitable solvents known in the art or combinations thereof may also be used, and the time of residency, volumes and mixing ratios may be varied based upon the cannabinoid(s) to be extracted. In some embodiments, the extract may be concentrated by evaporation of the solvent.
In some embodiments, a supercritical fluid may be used as an extractant. As discussed above, supercritical fluids are materials that are under sufficient pressure and heat that they are no longer distinctly liquid or gaseous; as a consequence, they have the penetrating power of gases and the solvating power of liquids. An example of a supercritical fluid is CO2, which is an accessible candidate because it can be made into a supercritical fluid above 32°C and 73 atmospheres.
Furthermore, adjustment of the temperature and pressure can vary the effective polarity of the supercritical fluid. In addition, it is of note that the addition of small quantities of other solvents as modifiers can assist in designing the appropriate solvent for specific target analytes. Thus, the supercritical fluid can be used to extract specific compounds from hemp extract based on their chemical properties. It is of note that other suitable supercritical fluids known in the art may also be used as solvents in some embodiments.
The extract is then passed through a chromatographic column, for example, an HPLC column or a reversed phase HPLC column. In one embodiment, the chromatographic column is arranged for fractioning 09-THC out of the eluent. That is, as the extract is passed over the column, a9-THC is differentially retained or detained on the the column. As a result, as the extract comes off the column, the initial fractions eluted off the column wilt be free of ~9-THC. These fractions free of ~9-THC are pooled, thereby praducing a whole hemp extract with O9-THC removed. In some embodiments, the a9-THC may be eluted from the column, extracted or concentrated, for purifying ~9-THC. In alternative embodiments, the chromatographic column is arranged for fractioning a specific cannabinoid, cannflavin or essential oil or class of cannabinoids, cannflavins or essential oils out of the eluent, for example, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarol (CBDV), tetrahydrocannabidiol (THCBD), tetrahydrocannabigerol (THCBG), tetrahydrocannabichromene (THCBC), tetrahydrocannabidivarol (THCBDV), ~a-THC, the carboxylic acid precursors of the foregoing compounds, and related naturally occurring compounds and their derivatives. It is of note that the provided list of compounds is by no means exhaustive and is in no way intended to be limiting. In these embodiments, the compounds) of interest are retained or detained on the column so that the last fractions of the extract eluted from the column contain the compounds(s) of interest. The fractions containing the compounds) of interest are pooled. In some embodiments, different compounds may be extracted with different solvents and then combined into a single extract. As will be appreciated by one knowledgeable in the art, in this manner, several different cannabinoids could be purified from a single extract.
EXAMPLE I - EXTRACTION PROTOCOL EXAMPLE
The chaff from the hemp is air dried or dehydrated. The chaff is then pulverized and extracted with agitation in a suitable solvent for a period of time. The solvent may be, for example, ethanol, toluene or hexane. The liquid extract is then separated from the solid component, for example, by filtration or other means known in the art. At this point, the extract may be concentrated (reduced in volume) or dried and resuspended in a new solvent.
In some embodiments, the foliar and floral material from the hemp may be subjected to supercritical fluid extraction for extracting cannabinoids, cannflavins andlor essential oils. In some embodiments, the supercritical fluid may be C02 or another supercritical fluid known in the art. In other embodiments, other solvents may be used as modifiers in combination with the supercritical fluid for targeted extraction of specific compounds, as discussed above.
' 10 EXAMPLE II -EXTRACTION PROTOCOL EXAMPLE
Individual components or analytes may be isolated from the above-described extract by subjecting the extract to high pressure liquid chromatography (HPLC) using, for example, a reversed phase C~s column and a mobile phase made up of for example acetonitrile and water or methanol and water for the isolation of cannabinoid and cannflavin compounds. For the isolation of the carboxylic analogs, small amounts of, for example, acetic or phosphoric acids are used. For the isolation of the essential oil components, normal phase chromatography is used with solvents such as hexane, toluene, or ethyl acetate as the mobile phase. Flow rates of for example 0.5 to 3.0 mUmin are used for the analytical separation, 3.0 to 100 mUmin for the preparative isolation on a pilot scale, or 50 to 500 mUmin for full scale production separation.
It is of note that the pooled fractions discussed above may be further concentrated by evaporation to yield extracts which are suitable for further treatment by means known in the art to produce, for example, tinctures, capsules, powders, pills, hemp oil-based or other oil-based capsules, topical applications, creams, salves, gels, drops, lotions, aerosols, sprays, injections and the like.
Alternatively, the pooled fractions may be crystallized.
It is of note that the extent to which the chaff is dried can be varied as can the time of storage from harvest of the industrial hemp to extraction of the ground chaff.
It is of note that in some embodiments, the specific cannabinoids isolated are those cannabinoids with suspected health benefits or suspected medicinal uses. For example, the cannabinoids and cannflavins may be used as anti-emetics, antinauseants, appetite stimulants, anti-inflammatories, antioxidants, neuroprotectives, analgesics, suppressants for primary immune response, glaucoma remedies, antineoplastics, migraine headache remedies, anticonvulsants, anti-epileptics, or movement disorder remedies. The essE:ntial oils may be used for aromatherapy or as flavoringlscenting adjuvants.
In alternative embodiments, other varieties of Cannabis may be used for extracting cannabinoids.
It is of note that solvent volume may be reduced prior to loading of the extract on the column or after fractionation of the extract. Alternatively, the solvent may be removed prior to loading the extract onto the column or after fractionation and the extract may then be suspended in another suitable solvent, for example, a low molecular weight alcohol.
While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.
FIELD OF THE INVENTION
The following invention relates generally to the field of methods of chemical purification: More specifically, the present invention relates to a method of producing natural health products from industrial hemp:
BACKGROUND OF THE tNVENTI:ON
Recently, public interest in Cannahis as medicine has been growing, based in no small part on the fact that Cannabis has long been considered to have medicinal properties, ranging from treatment of cramps, migraines, convulsions;
appetite stimulation and attenuation of nausea and vomiting. In fact; a report issued by the National Academy of Sciences' Institute of Medicine indicated that the active components of marijuana appear to be useful in treating pain, nausea, AIDS-related weight loss or "wasting", muscle spasms in multiple selerosiS as well as other problems. Advocates of medical marijuana argue that it is also useful for glaucoma, Parkinson's disease; Huntington's disease, migraines epilepsy and Alzheimer's dl ease.
Marijuana refers to varieties of Cannabis f~aving a high content of ~9 tetrahydrocannabinol (~9-THC), which is the psychoacfiive ingredient of marijuana whereas industrial hemp refers to varieties ofi the Cannabis plant that have a low content of O9-THC.
The controversy regarding the medicinal use of marijuana is centered not only on what is delivered but on how it is delivered. Specifically, the primary method used-to deliver marijuana into a patient's system is by smoking the marijuana;
however, smoking increases an individual's risk for cancer; Lung damage and emphysema. Furthermore, as discussed above, marijuana does contain high levels of a psychoactive drug, D9-THC. As such; there has been considerable debate as to whether or not the potential health benefits of smoking marijuana outweigh the health benefits.
However, it is of note that d9-THC is only one of a family of about 60 bl and tri- cyclic compounds named cannabinoids: These natural products usually contain a 1;1'-di-methyl-pyrane ring; a variedly derivatized aromatic ring and a variedly unsaturated cyclohexyl ring, and include for example the non-psychoactive cannabinol; cannabidiol and cannabinolic acid: These latter compounds have been suggested to contribute to some of he beneficial effects of Cannabis, such as cell protection, ,immunosuppression and ant-inflammatory properties. This suggests that these non-psychoactive cannabinoids recognize; the same cellular receptors as THC but, due to structural differences, do not have the same side effects.
Clearly, a process is needed for preparing natural health products containing 'the non-restricted compounds present in marijuana to be used for medicinal purposes.
SUMMARY OF THE INDENTION
According to a first aspect of the invention, there is provided a method of preparing a Cannabis extract comprising:
harvesting Cannabis. composed of seed and chaff;
separating the chaff from the seed;
extracting the chaff with a solvent, thereby producing an extract;
passing the extract over a chromatographic column arranged to fractionate 09-THC out of the extract; and collecting the fractions ' lacking D9-THC from the column, thereby producing a whole hemp extract without the d9-THC.
The chaff may be dried and/or the chaff may be ground prior to extraction.
The collected fractions may be concentrated.
The Cannabis may be industrial hemp:
The solvent may be an organic solvent; selected from the group consisting of: a petroleum derived hydrocarbon; toluene; trimethylpentane, a low molecular weight alcohol; ethanol; a low molecular weight chlorinated hydrocarbon;
and dichloromethane.
According to a second aspect of the invention, there is provided a hemp extract isolated according to the abova-describedmethod.
According to a thud aspect of the invention, there is provided a pharmaceutical composition comprising the hemp extract according to the above described method.
According to a fourth aspect of the invention; here is provided a method of extracting a cannabinoid, cannflavin or essential oil from Cannabis comprising:
harvesting Cannabis composed of seed and chaff;
separating the chaff from the sued;
extracting the chaff with a solvent, thereby producing an extract;
passing the extract over a chromatographic column arranged to fractionate the cannabinoid, cartnflavin or essential oil of interest out of the extract;
and collecting the fractions containing the cannabinoid; cannflavin or essential oil of interest from the column, pr~ducing a purified cannabinoid;
cannflavin or essential oil.
The cannabinoid may be selected from the group -consisting of:
cannabidiol (CBD); cannabinof (CBN); cannabigerol (CBG)cannabichromene (CBC);
cannabidivarol (CBDV); tetrahydrocannabidiol (THCBD); tetrahydrocannabigerol (THCBG); tetrahydrocannabichromene (THCBC); tetrahydrocannabidivarol (THCBDV); O$-THC; the carboxylic acid precursors of h~ foregoing compounds;
and related naturally occurring compounds and their derivatives.
The chaff may be dried andlor the chaff may be ground prior to extraction.
The collected fractions: may be concentrated::
The Cannabis may be industriai hemp.
The solvent may be an organic solvent, selected from the group consisting of: a petroleum derived hydrocarbon; toluene; trimethylpentane, a low molecular weight alcohol; ethanol; a low molecular weight chlorinated hydrocarbon;
and dichloromethane.
According to a fifth aspect of the invention, there is provided a purified cannabinoid, cannflavin or essential oil prepared according to the above-described method.
According to a sixth aspect of the invention, there is provided a pharmaceutical composition comprising the purified cannabinoid, cannflavin or 5 essential oil prepared according the above-described method.
The invention will now be described by way of examples, although the invention is not in any way limited to the examples described herein.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.
DEFINITIONS
As used herein, "industrial hemp" refers to varieties of the Cannabis plant that have a low content of ~9-tetrahydrocannabinol (D9-THC).
As used herein, "supercritical fluid" refers to materials that are under sufficient pressure and heat that they are no longer distinctly liquid or gaseous.
As used herein, "cannabinoids" refers to a family of natural products that usually contain a 1,1'-di-methyl-pyrane ring, a variedly derivatized aromatic ring and a variedly unsaturated cyclohexyl ring and their immediate chemical precursors.
Described herein is a method of processing industrial hemp and extracting cannabinoids, cannflavins or essential oils therefrom. In one embodiment, the extract is run over a column that fractionates O9-tetrahydrocannabinol out of the extract, thereby producing an eluent that is free of a9-THC. The eluent may then be concentrated or otherwise treated by means known in the art to produce a natural health product, that is, a whole hemp extract with they ~9-THC removed. In some embodiments, the fractions containing D9-THC may be collected or pooled or the extracted ~9-THC may be eluted. In another embodiment, the extract is run over a column arranged to fractionate a specific cannabinoid or class of cannabinoids other than o9-THC. In this embodiment, the fractions containing the cannabinoid, cannflavin or essential oil or class of cannflavins, cannabinoids or essential oils of interest are collected, thereby producing purified cannabinoid(s), cannflavin(s) and/or essential oil(s). Compounds isolated by this method may include but are by no means limited to, for example, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarol (CBDV), tetrahydrocannabidiol (THCBD), tetrahydrocannabigerol (THCBG), tetrahydrocannabichromene (THCBC), tetrahydrocannabidivarol (THCBDV), O8-THC, the carboxylic acid precursors of the foregoing compounds, and related naturally occurring compounds and their derivatives.
The invention will now be described by way of examples; however, the invention is in no way limited to these examples.
In the example described herein, industrial hemp is harvested and the hemp seeds are threshed from the chaff. The chaff is collected and may then be dried or extracted green. In the embodiment described herein, the chaff is dried and is then finely divided, ground or pulverized. The ground chaff is then extracted with a solvent.
In this embodiment, the time of residency of the ground chaff in the solvent is up to approximately 2-4 hours. Furthermore, the mixing ratio o~f chaff to solvent is such that the chaff can be suspended in the extracting medium during the extraction process.
Specifically, in this embodiment the volume ratio is between 10:1 to 100:1.
The solvent may be an organic solvent, for example, a petroleum derived hydrocarbon such as for example toluene or trimethylpentane, a low molecular weight alcohol such as for example ethanol, or a low molecular weight chlorinated hydrocarbon such as for example dichloromethane. As will be appreciated by one knowledgeable in the art, other suitable solvents known in the art or combinations thereof may also be used, and the time of residency, volumes and mixing ratios may be varied based upon the cannabinoid(s) to be extracted. In some embodiments, the extract may be concentrated by evaporation of the solvent.
In some embodiments, a supercritical fluid may be used as an extractant. As discussed above, supercritical fluids are materials that are under sufficient pressure and heat that they are no longer distinctly liquid or gaseous; as a consequence, they have the penetrating power of gases and the solvating power of liquids. An example of a supercritical fluid is CO2, which is an accessible candidate because it can be made into a supercritical fluid above 32°C and 73 atmospheres.
Furthermore, adjustment of the temperature and pressure can vary the effective polarity of the supercritical fluid. In addition, it is of note that the addition of small quantities of other solvents as modifiers can assist in designing the appropriate solvent for specific target analytes. Thus, the supercritical fluid can be used to extract specific compounds from hemp extract based on their chemical properties. It is of note that other suitable supercritical fluids known in the art may also be used as solvents in some embodiments.
The extract is then passed through a chromatographic column, for example, an HPLC column or a reversed phase HPLC column. In one embodiment, the chromatographic column is arranged for fractioning 09-THC out of the eluent. That is, as the extract is passed over the column, a9-THC is differentially retained or detained on the the column. As a result, as the extract comes off the column, the initial fractions eluted off the column wilt be free of ~9-THC. These fractions free of ~9-THC are pooled, thereby praducing a whole hemp extract with O9-THC removed. In some embodiments, the a9-THC may be eluted from the column, extracted or concentrated, for purifying ~9-THC. In alternative embodiments, the chromatographic column is arranged for fractioning a specific cannabinoid, cannflavin or essential oil or class of cannabinoids, cannflavins or essential oils out of the eluent, for example, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarol (CBDV), tetrahydrocannabidiol (THCBD), tetrahydrocannabigerol (THCBG), tetrahydrocannabichromene (THCBC), tetrahydrocannabidivarol (THCBDV), ~a-THC, the carboxylic acid precursors of the foregoing compounds, and related naturally occurring compounds and their derivatives. It is of note that the provided list of compounds is by no means exhaustive and is in no way intended to be limiting. In these embodiments, the compounds) of interest are retained or detained on the column so that the last fractions of the extract eluted from the column contain the compounds(s) of interest. The fractions containing the compounds) of interest are pooled. In some embodiments, different compounds may be extracted with different solvents and then combined into a single extract. As will be appreciated by one knowledgeable in the art, in this manner, several different cannabinoids could be purified from a single extract.
EXAMPLE I - EXTRACTION PROTOCOL EXAMPLE
The chaff from the hemp is air dried or dehydrated. The chaff is then pulverized and extracted with agitation in a suitable solvent for a period of time. The solvent may be, for example, ethanol, toluene or hexane. The liquid extract is then separated from the solid component, for example, by filtration or other means known in the art. At this point, the extract may be concentrated (reduced in volume) or dried and resuspended in a new solvent.
In some embodiments, the foliar and floral material from the hemp may be subjected to supercritical fluid extraction for extracting cannabinoids, cannflavins andlor essential oils. In some embodiments, the supercritical fluid may be C02 or another supercritical fluid known in the art. In other embodiments, other solvents may be used as modifiers in combination with the supercritical fluid for targeted extraction of specific compounds, as discussed above.
' 10 EXAMPLE II -EXTRACTION PROTOCOL EXAMPLE
Individual components or analytes may be isolated from the above-described extract by subjecting the extract to high pressure liquid chromatography (HPLC) using, for example, a reversed phase C~s column and a mobile phase made up of for example acetonitrile and water or methanol and water for the isolation of cannabinoid and cannflavin compounds. For the isolation of the carboxylic analogs, small amounts of, for example, acetic or phosphoric acids are used. For the isolation of the essential oil components, normal phase chromatography is used with solvents such as hexane, toluene, or ethyl acetate as the mobile phase. Flow rates of for example 0.5 to 3.0 mUmin are used for the analytical separation, 3.0 to 100 mUmin for the preparative isolation on a pilot scale, or 50 to 500 mUmin for full scale production separation.
It is of note that the pooled fractions discussed above may be further concentrated by evaporation to yield extracts which are suitable for further treatment by means known in the art to produce, for example, tinctures, capsules, powders, pills, hemp oil-based or other oil-based capsules, topical applications, creams, salves, gels, drops, lotions, aerosols, sprays, injections and the like.
Alternatively, the pooled fractions may be crystallized.
It is of note that the extent to which the chaff is dried can be varied as can the time of storage from harvest of the industrial hemp to extraction of the ground chaff.
It is of note that in some embodiments, the specific cannabinoids isolated are those cannabinoids with suspected health benefits or suspected medicinal uses. For example, the cannabinoids and cannflavins may be used as anti-emetics, antinauseants, appetite stimulants, anti-inflammatories, antioxidants, neuroprotectives, analgesics, suppressants for primary immune response, glaucoma remedies, antineoplastics, migraine headache remedies, anticonvulsants, anti-epileptics, or movement disorder remedies. The essE:ntial oils may be used for aromatherapy or as flavoringlscenting adjuvants.
In alternative embodiments, other varieties of Cannabis may be used for extracting cannabinoids.
It is of note that solvent volume may be reduced prior to loading of the extract on the column or after fractionation of the extract. Alternatively, the solvent may be removed prior to loading the extract onto the column or after fractionation and the extract may then be suspended in another suitable solvent, for example, a low molecular weight alcohol.
While the preferred embodiments of the invention have been described above, it will be recognized and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.
Claims (16)
1. A method of preparing a Cannabis extract comprising:
harvesting Cannabis composed of seed and chaff;
separating the chaff from the seed;
extracting the chaff with a solvent, thereby producing an extract;
passing the extract over a chromatographic column arranged to fractionate at least one cannabinoid, cannflavin or essential oil out of the extract; and collecting the fractions lacking said at least one cannabinoid, cannflavin or essential oil from the column, thereby producing a hemp extract and at least one purified cannabinoid, cannflavin or essential oil.
harvesting Cannabis composed of seed and chaff;
separating the chaff from the seed;
extracting the chaff with a solvent, thereby producing an extract;
passing the extract over a chromatographic column arranged to fractionate at least one cannabinoid, cannflavin or essential oil out of the extract; and collecting the fractions lacking said at least one cannabinoid, cannflavin or essential oil from the column, thereby producing a hemp extract and at least one purified cannabinoid, cannflavin or essential oil.
2. The method according to claim 1 including drying the chaff prior to extraction.
3. The method according to claim 1 or 2 including grinding the chaff prior to extraction.
4. The method according to any one of claims 1-3 including concentrating the collected fractions.
5. The method according to any one of claims 1-4 wherein the Cannabis is industrial hemp.
6. The method according to any one of claims 1-5 wherein the solvent is an organic solvent.
7. The method according to claim 6 wherein the organic solvent is selected from the group consisting of: a petroleum derived hydrocarbon;
toluene;
trimethylpentane, a low molecular weight alcohol; ethanol; a low molecular weight chlorinated hydrocarbon; and dichloromethane.
toluene;
trimethylpentane, a low molecular weight alcohol; ethanol; a low molecular weight chlorinated hydrocarbon; and dichloromethane.
8. The method according to any one of claims 1 to 7 wherein the purified cannabinoid is selected from the group consisting of: .DELTA.9-THC;
cannabidiol (CBD); cannabinol (CBN); cannabigerol (CBG); cannabichromene (CBC);
cannabidivarol (CBDV); tetrahydrocannabidiol (THCBD); tetrahydrocannabigerol (THCBG); tetrahydrocannabichromene (THCBC); tetrahydrocannabidivarol (THCBDV); .DELTA.8-THC; the carboxylic acid precursors of the foregoing compounds; and related naturally occurring compounds and their derivatives.
cannabidiol (CBD); cannabinol (CBN); cannabigerol (CBG); cannabichromene (CBC);
cannabidivarol (CBDV); tetrahydrocannabidiol (THCBD); tetrahydrocannabigerol (THCBG); tetrahydrocannabichromene (THCBC); tetrahydrocannabidivarol (THCBDV); .DELTA.8-THC; the carboxylic acid precursors of the foregoing compounds; and related naturally occurring compounds and their derivatives.
9. The method according to any one of claims 1-7 wherein the purified cannflavin is selected from the group consisting of: cannflavin A;
cannflavin B; precursors of the foregoing compounds; and related naturally occurring compounds and their derivatives.
cannflavin B; precursors of the foregoing compounds; and related naturally occurring compounds and their derivatives.
10. The method according to any one of claims 1-9 wherein the extraction is performed using subcritical water.
11. The method according to any one of claims 1-9 wherein the extraction is performed using steam.
12. The method according to claim 1 wherein the solvent is a supercritical fluid.
13. The method according to claim 12 wherein the solvent includes modifier compounds.
14. The method according to claim 12 wherein the supercritical fluid is CO2.
15. A cannabinoid, cannflavin or essential oil isolated according to the method of any one of claims 1-14.
16. A hemp extract prepared according to the method of any one of claims 1-14.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2391454 CA2391454A1 (en) | 2002-06-25 | 2002-06-25 | Cannabinoid extraction method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2391454 CA2391454A1 (en) | 2002-06-25 | 2002-06-25 | Cannabinoid extraction method |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2391454A1 true CA2391454A1 (en) | 2003-12-25 |
Family
ID=30449924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2391454 Abandoned CA2391454A1 (en) | 2002-06-25 | 2002-06-25 | Cannabinoid extraction method |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2391454A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10143706B2 (en) | 2016-06-29 | 2018-12-04 | Cannscience Innovations, Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
US10611713B2 (en) | 2018-03-09 | 2020-04-07 | Tianru Chen | Automated production line for preparing cannabidiol extract |
US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
-
2002
- 2002-06-25 CA CA 2391454 patent/CA2391454A1/en not_active Abandoned
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10143706B2 (en) | 2016-06-29 | 2018-12-04 | Cannscience Innovations, Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
US10383892B2 (en) | 2016-06-29 | 2019-08-20 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
US10537592B2 (en) | 2016-06-29 | 2020-01-21 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
US10611713B2 (en) | 2018-03-09 | 2020-04-07 | Tianru Chen | Automated production line for preparing cannabidiol extract |
US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6403126B1 (en) | Cannabinoid extraction method | |
Qamar et al. | Extraction of medicinal cannabinoids through supercritical carbon dioxide technologies: A review | |
AU2002218242B2 (en) | Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts | |
CA3027108C (en) | Purification and separation techniques for cannabinoids | |
US11192870B2 (en) | Continuous isolation of cannabidiol and conversion of cannabidiol to delta 8-tetrahydrocannabinol and delta 9-tetrahydrocannabinol | |
CA3059227A1 (en) | Isolation of pure cannabinoids from cannabis | |
EP2844243B1 (en) | Method for preparing a cannabis plant isolate comprising delta-9-tetrahydrocannabinol | |
US20170333503A1 (en) | Process for extraction, separation and purification of cannabinoids, flavonoids and terpenes from cannabis | |
US20030017216A1 (en) | Isolation of herbal and cannabinoid medicinal extracts | |
RU2359666C2 (en) | Method of allocation of secoisolariciresinol and dihydroquerticin from wood (versions) | |
JPH03170495A (en) | Method for producing isoflavones | |
KR102256712B1 (en) | Method of isolating cannabidiol from Cannabis sp. and uses thereof | |
EP1542984A2 (en) | Methods of purifying cannabinoids from plant material | |
WO2004026802A1 (en) | Method of preparing cannabidiol from plant material | |
WO2019145552A1 (en) | Methods of purifying cannabinoids using liquid:liquid chromatography | |
CN114539032A (en) | Method for preparing ultrapure cannabidiol monomer | |
EP4208274B1 (en) | Method of obtaining thc-free cannabinoid concentrate | |
AU2004303593A1 (en) | Process for purifying (-)-delta9-trans-tetrahydrocannabinol | |
CA2391454A1 (en) | Cannabinoid extraction method | |
EP4431169A1 (en) | Method of purifying cannabinoid components from plant extracts | |
Calmanti et al. | From Hemp to CBD Crystals: A Scaled-Up Procedure for the Selective Extraction, Isolation, and Purification of Cannabidiol | |
WO2023146536A1 (en) | High yield extraction method for and products of rhodiola plants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |